Biocept has launched its 12-gene Target Selector next-generation sequencing (NGS) breast panel, which analyzes both circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) for common biomarkers associated with breast cancer.
The breast cancer panel, which is designed for use with Thermo Fisher Scientific's Ion Torrent NGS platform, has sensitivity of more than 90%, specificity of more than 99%, and accuracy of 99.8%, according to Biocept. It is the second Target Selector product to be introduced, after a panel for lung cancer. The company also offers single-biomarker testing on its ctDNA and CTC platforms.
